Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence

Area of Science:

• Immunology
• Cancer Biology
• Oncology

Background:

• Minimal residual disease (MRD) can transition into treatment-resistant, immune-invisible recurrent tumors.
• Understanding this transition is crucial for developing effective cancer therapies.

Purpose of the Study:

• To investigate how incompletely cleared primary tumors evolve into treatment-resistant MRD.
• To identify the mechanisms by which MRD evades innate immunosurveillance.
• To explore therapeutic strategies to prevent tumor recurrence.

Main Methods:

• Analysis of the roles of TNFα and cytokine profiles (IL6, IFNγ) in MRD progression.
• Investigation of NK-cell and T-cell surveillance evasion by PD-L1-expressing MRD cells.
• Evaluation of stimuli (VEGF, TNFα) promoting MRD growth.
• Assessment of therapeutic interventions including PD-1, TNFα, and NK cell blockade.

Main Results:

• TNFα shifts from an anti-tumor effector to a growth promoter for MRD.
• PD-L1-high MRD cells induce IL6 secretion and inhibit IFNγ, impairing NK-cell and T-cell surveillance.
• Trauma or infection-like stimuli promote MRD growth via VEGF and TNFα.
• Blocking PD-1, TNFα, or NK cells delays or prevents tumor recurrence.

Conclusions:

• Innate immunosurveillance mechanisms are subverted by recurrent tumors, enabling immune evasion.
• Therapeutic strategies targeting PD-1, TNFα, and NK cells show promise in preventing MRD recurrence.
• These findings identify potential therapeutic targets for high-risk MRD patients prone to relapse.